MNPR vs HELP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MNPR · Monopar Therapeutics$69.00 ▼ 1.84%
HELP · Cybin$6.11 ▼ 9.88%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MNPR -25.6%
- HELP +3.7%
Head to head
| Metric | MNPR | HELP |
|---|---|---|
| Price | $69.00 | $6.11 |
| Change today | ▼ 1.84% | ▼ 9.88% |
| Market cap | $467.60M | $487.62M |
| Return, 3 months | -38.0% | -53.1% |
| Return, year to date | +5.7% | -25.3% |
| Return, 1 year | -24.6% | +9.3% |
| P/E (TTM) | – | – |
| P/B | 3.7 | 2.0 |
| P/E percentile vs own 5y | 12th | 34th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -80.3% | -94.3% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -15.3% | -86.9% |
| Analyst target vs. price | +86.5% | +573.8% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 40 | 24 |
| 30-day volatility | 53.1% | 89.2% |
| Max drawdown, 1 year | -46.5% | -56.4% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HELP is the largest of the group by market value.
- HELP has returned the most over the past year.
- MNPR has been the calmest stock over the last 30 days.